Assigned Patents. Assigned Patents" means only those
Assigned Patents. Subject to Sections 2.2 and 2.3 below, Adaptec hereby grants, conveys and assigns (and agrees to cause its appropriate Subsidiaries to grant, convey and assign) to Roxio, by execution hereof (or, where appropriate or required, by execution of separate instruments of assignment), all its (and their) right, title and interest in and to the Assigned Patents, to be held and enjoyed by Roxio, its successors and assigns. Adaptec further grants, conveys and assigns (and agrees to cause its appropriate Subsidiaries to grant, convey and assign) to Roxio all its (and their) right, title and interest in and to any and all causes of action and rights of recovery for past infringement of the Assigned Patents and the right to claim priority from the Assigned Patents. Adaptec will, without demanding any further consideration therefor, at the request and expense of Roxio (except for the value of the time of Adaptec employees), do (and cause its Subsidiaries to do) all lawful and just acts, that may be or become necessary for prosecuting, sustaining, obtaining continuations, continuations-in-part and divisionals of, or reissuing or re-examining, said Assigned Patents and for evidencing, maintaining, recording and perfecting Roxio's rights to said Assigned Patents, including but not limited to execution and acknowledgement of (and causing its Subsidiaries to execute and acknowledge) assignments and other instruments in a form reasonably required by Roxio for each Patent jurisdiction.
Assigned Patents. Del Mar shall, at its own expense and at its discretion, file, maintain, prosecute and defend all Assigned Patents. At the request of Del Mar, Valent shall provide reasonable cooperation in connection with such filing, prosecution, maintenance or defense. Del Mar shall reimburse Valent for any reasonable out-of-pocket expenses or costs incurred in connection with such cooperation.
Assigned Patents. For the avoidance of doubt, the Assigned Patents includes (i) any substitutions, extensions, additions, reissues, reexaminations, renewals, divisions, continuations, continuations-in-part, or supplementary protection certificates, or patents or pending patent applications claiming priority, to the following patents, and (ii) all foreign counterparts of any of the following patents or those listed in clause (i). Country Application # Owner Application Date U.S.A. 62/323,904 Espero Pharmaceuticals, Inc. 04/18/2016 U.S.A. PCT/US2017/027887 Espero Pharmaceuticals, Inc. 04/17/2017 U.S.A. 15/131,446 Espero Pharmaceuticals, Inc. 04/18/2016 U.S.A. PCT/US2017/027883 Espero Pharmaceuticals, Inc. 04/18/2017 U.S.A. 15/131,478 Espero Pharmaceuticals, Inc. 04/18/2016 U.S.A. PCT/US2017/027886 Espero Pharmaceuticals, Inc. 04/17/2017 Country Registration # Owner Registration Date Tecarfarin U.S.A. 7666902 Espero BioPharma, Inc. 02/23/2010 U.S.A. 7145020 Espero BioPharma, Inc. 12/05/2006 Country Application # Owner Application Date U.S.A. 7932405 Espero BioPharma, Inc. 04/26/2011 U.S.A. 7253208 Espero BioPharma, Inc. 08/07/2007 U.S.A. 7285671 Espero BioPharma, Inc. 10/23/2007 Australia 2005233614 Espero BioPharma, Inc. 7/12/2012 Austria 1735296 Espero BioPharma, Inc. 12/9/2009 Belgium 1735296 Espero BioPharma, Inc. 12/9/2009 Belgium 2161261 Espero BioPharma, Inc. 8/28/2013 Brazil PI0508392-3 Espero BioPharma, Inc. Canada 2559568 Espero BioPharma, Inc. 5/28/2013 China 200580012074.6 Espero BioPharma, Inc. 6/1/2011 Cyprus 1735296 Espero BioPharma, Inc. 12/9/2009 Denmark 1735296 Espero BioPharma, Inc. 12/9/2009 Denmark 2161261 Espero BioPharma, Inc. 8/28/2013 Country Application # Owner Application Date Europe 05733799.0 Espero BioPharma, Inc. 12/9/2009 Europe 09175606.4 Espero BioPharma, Inc. 8/28/2013 Finland 1735296 Espero BioPharma, Inc. 12/9/2009 Finland 2161261 Espero BioPharma, Inc. 8/28/2013 France 1735296 Espero BioPharma, Inc. 12/9/2009 France 2161261 Espero BioPharma, Inc. 8/28/2013 Germany 602005018181.4 Espero BioPharma, Inc. 12/9/2009 Germany 602005041073.2 Espero BioPharma, Inc. 8/28/2013 Great Britain 1735296 Espero BioPharma, Inc. 12/9/2009 Great Britain 2161261 Espero BioPharma, Inc. 8/28/2013 Greece 3071104 Espero BioPharma, Inc. 12/9/2009 Hong Kong 1105200 Espero BioPharma, Inc. 3/9/2012 Hong Kong 1138265 Espero BioPharma, Inc. 5/23/2014 India 250594 Espero BioPharma, Inc. 1/11/2012 Ireland 1735296 Espero BioPharma, Inc. 12/9/2009 Ireland 2161261 Espero Bio...
Assigned Patents. Subject to the terms and conditions contained herein, and subject to TAKEDA’s receipt of TOBIRA’s payment of the upfront milestone pursuant to Article 4.A.(i), TAKEDA shall assign and transfer irrevocably (but subject to TAKEDA’s right to request to transfer and/or abandon pursuant to Article 17.B.(c) hereof) to TOBIRA and TOBIRA shall accept such assignment and transfer and take over the patents and patent applications listed in the patent list attached hereto as Schedule 1(5), in accordance with the terms and conditions herein; provided, however, TAKEDA may, before such assignment, delete, amend or disclaim the claimed inventions other than those of the Compounds(i.e., claimed inventions of the composition of matter of the Compounds per se) from such patents and patent applications and move such deleted, amended or disclaimed inventions, in part or whole, into other patent(s) and patent application(s) derived therefrom (the patents and patent applications listed in the patent list attached hereto as Schedule 1(5), after such deletion, amendment, disclaimer, if taken, shall be hereinafter called the “Assigned Patents” and the patents and patent applications thus made by moving the [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. deleted, amended or disclaimed inventions shall be hereinafter called the “Other Patents”.). TAKEDA shall take necessary procedures for such deletion, amendment and disclaimer within three (3) months after the receipt of TOBIRA’s payment of the upfront milestone pursuant to Article 4.A.(i). For the avoidance of doubt, TAKEDA shall not be under any obligations to, including without limitation obligation to prosecute or maintain, the Other Patents , and TAKEDA shall be entitled to dispose of , abandon or modify such Other Patents at its sole discretion, provided, however, if such Other Patents fall under the definition of the Ancillary Patents set forth in Article 2.B., then such Other Patents shall be added to and treated as the Ancillary Patents. If TAKEDA desires to dispose of or abandon the part or scope of the Other Patents which part or scope covers the inventions of the Specific Compounds (i.e., the composition of matter of the Specific Compounds per se) (hereinafter called the “Specific Compounds Scope”), TAKEDA shall provide TOBIRA with thirty (30) days prior written noti...
Assigned Patents. Sellers’ representations, warranties and disclosures set forth in this Section 3.2 and Section 3.3 (to the extent Section 3.3 deals with the Assigned Patents) shall not apply to any fact, circumstance or matter arising prior to the period before July 29, 2011 (the “Ownership Date”) even if such fact, circumstance or matter continued or continues after the Ownership Date (the 10 “Nortel Exception”); provided that Sellers’ representations and warranties shall be to Sellers’ Knowledge (even prior to the Ownership Date) where Sellers’ Knowledge is indicated in this Section 3.2. Sellers’ representations, warranties and disclosures set forth in this Section 3.2 and Section 3.3 (to the extent Section 3.3 deals with the Assigned Patents) shall not apply to any Jointly Owned Patent(s) to the extent that such representations, warranties and/or disclosures are inaccurate or incorrect as a result of any failure to obtain any consent or waiver required for the assignment thereof, whether at Law or pursuant to any Existing Encumbrance, including, without limitation, any joint ownership agreement.
Assigned Patents. Docket No. Patent Xxx.Xx./Pub No/Patent No. Location Status/Validation [ * ] [ * ] [ * ] [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 1.38
Assigned Patents. The Assigned Patents, subject to the terms and conditions of this Agreement, are those assocated with the following Agilent patent families: 190579 10010745 10020825 10030979 10040644 190596 10010816 10020851 10030985 10040670 191257 10010835 10020880 10031023 10040678 191528 10010869 10020917 10031048 10040679 191610 10010880 10020981 10031075 10040748 490051 10010980 10021061 10031166 10040886 10001804 10011095 10021089 10031220 10040907 10001940 10011122 10021092 10031229 10040927 10002352 10011125 10021116 10031230 10040959 10003329 10011162 10021119 10031276 10041015 10003336 10011201 10021216 10031298 10041025 10003342 10011219 10021250 10031301 10041043 10003845 10011298 10030041 10031355 10041057 10003879 10011300 10030042 10031555 10041086 10003880 10011302 10030056 10031556 10041127 10003976 10011338 10030059 10031564 10041143 10004017 10011355 10030061 10040010 10041158 10004048 10011387 10030094 10040025 10041159 10004095 10020043 10030114 10040032 10041239 10004195 10020076 10030186 10040033 10041240 10004221 10020111 10030268 10040054 10041242 10004222 10020154 10030335 10040055 10041244 10004384 10020205 10030362 10040070 10041248 10004402 10020206 10030379 10040101 10041249 10010023 10020245 10030469 10040152 10041253 10010274 10020417 10030610 10040292 10041315 10010323 10020454 10030611 10040321 10041316 10010334 10020524 10030612 10040352 10041325 10010400 10020532 10030724 10040476 10041328 10010403 10020610 10030762 10040481 10041329 10010493 10020611 10030838 10040492 10041333 10010657 10020693 10030919 10040569 10041382 10010689 10020725 10030972 10040580 10041390 10041504 10051506 10060349 10070124 1093738 10041556 10051635 10060353 10070146 1093804 10041568 10051689 10060354 10070147 1093811 10041598 10051691 10060356 10070162 1093854 10041666 10051694 10060358 10070176 1094280 10041675 10051738 10060360 10070192 1094336 10041676 10051739 10060365 10070194 1094401 10050020 10051740 10060366 10070219 1094470 10050034 10051743 10060368 10070220 1094576 10050041 10060031 10060374 10070239 1094643 10050124 10060044 10060412 10070251 1094669 10050125 10060051 10060426 10070262 1094725 10050132 10060059 10060448 10070265 1094750 10050137 10060075 10060449 10070276 1094752 10050156 10060101 10060459 10070290 1094769 10050196 10060122 10060463 10070292 1094855 10050203 10060135 10060491 10070328 1094862 10050204 10060138 10060493 10070329 1094892 10050214 10060146 10060501 10070330 1094956 10050216 10060157 10060521 10070331 1094957 100503...
Assigned Patents. The 675 Patent and/or the 787 Patent, as the case may be.
Assigned Patents. “Assigned Patents” means all Patents identified in Schedule C, attached hereto as part of this IPAL Agreement, including any Foreign Counterparts.
